Posted by Michael Wonder on 10 Jun 2021
NICE recommends several treatment options to help thousands with moderate rheumatoid arthritis
10 June 2021 - Around 25,000 people with moderate rheumatoid arthritis that has not responded to conventional therapies are set to benefit from the recommendations announced today.
Adalimumab, etanercept and infliximab, taken with methotrexate have been recommended for use within the NHS. Adalimumab and etanercept can also be used as monotherapy when methotrexate is contra-indicated or not tolerated.
